Here, we investigated the immunomodulatory potential of the SA-FasL microgel technology in a preclinical streptozotocin (STZ)–induced diabetes NHP model in which allogeneic islets and SA-FasL microgels are cotransplanted to the omental pouch. Here, FASLG is linked to diabetes mellitus.